百利天恒(688506.SH)：SI-B036雙特異性抗體注射液獲批在晚期實體瘤中開展臨床試驗

智通財經

05/14

智通財經APP訊，百利天恒(688506.SH)公告，公司近日收到國家藥品監督管理局(NMPA)正式批准簽發的《藥物臨床試驗批准通知書》，公司自主研發的創新生物藥SI-B036雙特異性抗體注射液的藥物臨床試驗獲得批准，同意該品單藥在晚期實體瘤中開展臨床試驗。

據悉，SI-B036雙特異性抗體注射液是公司自主研發的全球領先的特異性增強雙特異性抗體平台(SEBA平台)的產品之一，SEBA分子不僅可以提高靶向性和抗腫瘤活性，還可以最大限度地減少脫靶效應。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2635379062"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2635379062\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2635379062?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-05-14 17:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635379062","market":"us","top_or_hot":-1,"title":"百利天恒(688506.SH)：SI-B036雙特異性抗體注射液獲批在晚期實體瘤中開展臨床試驗","media":"智通財經","content":"<html><body><p>智通財經APP訊，<a href=\"https://laohu8.com/S/688506\">百利天恒</a>(688506.SH)公告，公司近日收到國家藥品監督管理局(NMPA)正式批准簽發的《藥物臨床試驗批准通知書》，公司自主研發的創新生物藥SI-B036雙特異性抗體注射液的藥物臨床試驗獲得批准，同意該品單藥在晚期實體瘤中開展臨床試驗。</p><p>據悉，SI-B036雙特異性抗體注射液是公司自主研發的全球領先的特異性增強雙特異性抗體平台(SEBA平台)的產品之一，SEBA分子不僅可以提高靶向性和抗腫瘤活性，還可以最大限度地減少脫靶效應。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百利天恒(688506.SH)：SI-B036雙特異性抗體注射液獲批在晚期實體瘤中開展臨床試驗</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百利天恒(688506.SH)：SI-B036雙特異性抗體注射液獲批在晚期實體瘤中開展臨床試驗\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經</strong><span class=\"h-time small\">2026-05-14 17:21</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p>智通財經APP訊，<a href=\"https://laohu8.com/S/688506\">百利天恒</a>(688506.SH)公告，公司近日收到國家藥品監督管理局(NMPA)正式批准簽發的《藥物臨床試驗批准通知書》，公司自主研發的創新生物藥SI-B036雙特異性抗體注射液的藥物臨床試驗獲得批准，同意該品單藥在晚期實體瘤中開展臨床試驗。</p><p>據悉，SI-B036雙特異性抗體注射液是公司自主研發的全球領先的特異性增強雙特異性抗體平台(SEBA平台)的產品之一，SEBA分子不僅可以提高靶向性和抗腫瘤活性，還可以最大限度地減少脫靶效應。</p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.zhitongcaijing.com/content/detail/1441753.html\">智通財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"醫療保健設備","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1441753.html","article_id":"2635379062","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635379062","pubTimestamp":1778750492,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通財經APP訊，百利天恒(688506.SH)公告，公司近日收到國家藥品監督管理局(NMPA)正式批准簽發的《藥物臨床試驗批准通知書》，公司自主研發的創新生物藥SI-B036雙特異性抗體注射液的藥物臨床試驗獲得批准，同意該品單藥在晚期實體瘤中開展臨床試驗。據悉，SI-B036雙特異性抗體注射液是公司自主研發的全球領先的特異性增強雙特異性抗體平台(SEBA平台)的產品之一，SEBA分子不僅可以提高靶向性和抗腫瘤活性，還可以最大限度地減少脱靶效應。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"91194":"临工重机股份有限公司（临时代码）","688506":"百利天恒","BK4082":"医疗保健设备","02615":"百利天恒","BK0239":"医药制造","BK4211":"区域性银行","SI":"Shoulder Innovations, Inc."},"translate_title":"Baili Tianheng (688506.SH): SI-B036 bispecific antibody injection approved for clinical trials in advanced solid tumors","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"91194":1.5,"688506":1.5,"SI":1.5,"02615":1.5},"content_text":"智通財經APP訊，百利天恒(688506.SH)公告，公司近日收到國家藥品監督管理局(NMPA)正式批准簽發的《藥物臨床試驗批准通知書》，公司自主研發的創新生物藥SI-B036雙特異性抗體注射液的藥物臨床試驗獲得批准，同意該品單藥在晚期實體瘤中開展臨床試驗。據悉，SI-B036雙特異性抗體注射液是公司自主研發的全球領先的特異性增強雙特異性抗體平台(SEBA平台)的產品之一，SEBA分子不僅可以提高靶向性和抗腫瘤活性，還可以最大限度地減少脱靶效應。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}